Abstract
Rectal administration is preferred to oral and parenteral routes in paediatric population because it is relatively painless while avoiding nausea, vomiting and first pass metabolism. With emergence of chloroquine resistance, quinine is still one of the accepted chemotherapeutic agents against Plasmodium falciparum. The aim of this study is to develop paediatric suppositories of quinine sulphate using FattibaseTM to aid stability, adequate release, ease of administration and affordability. Physical appearance, weight uniformity, hardness, melting range, liquefaction time, drug content uniformity, FTIR and release profile of the suppositories were determined at 27.0±2.0 ᵒC and 4.0±0.5 ᵒC after 0, 1, 4 and 8 weeks. Statistical analysis was done using two-way ANOVA.  FTIR analysis revealed no significant modification occurred in the chemical structure of quinine throughout storage. For suppositories stored at 27.0±2.0 ᵒC, hardness and liquefaction time increased significantly with time. Release of quinine from the fattibaseTM was sustained (quantity released at 120 min, Q120 = 52.16 - 71.16%). Storage time had significant influence (p< 0.05) on all the parameters while storage temperature significantly influenced hardness, liquefaction time, Q120 and drug content. Quinine sulphate suppositories made with fattibaseTM were stable throughout the period of study and will be suitable for peadiatric use
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
